Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886535 · ClinicalTrials.gov registry record
Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity
A clinical trial, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- 41
- Enrollment target
NCT00886535: Completed study, sponsored by Milton S. Hershey Medical Center.
NCT00886535 is a clinical trial that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00886535 has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen. Pre- and post-menopausal women taking tamoxifen as standard therapy or chemopreventive therapy will be included in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-02 |
| Est. Completion | 2017-07-27 |
What the finished NCT00886535 record still lists
NCT00886535 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00886535 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00886535 about?
NCT00886535 is a clinical study titled "Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity". This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen. Pre- and post-menopausal women taking tamoxifen as standard therapy or chemopreventive therapy will be included in this study.
What is the current status of trial NCT00886535?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2010-02. Estimated completion is 2017-07-27.
Who is sponsoring clinical trial NCT00886535?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia